Summary & Overview
HCPCS J7611: Albuterol Inhalation Solution, Concentrated 1 mg
HCPCS Level II code J7611 represents an FDA-approved, non-compounded, concentrated albuterol inhalation solution (1 mg) supplied for administration via durable medical equipment. Nationally, this code is used to identify the specific drug formulation when billed separately from DME or professional services, affecting coverage determinations, reimbursement workflows, and pharmacy-DME coordination. The code matters for providers, payers, and DME suppliers because formulation, concentration, and FDA approval status can drive coverage criteria and claim adjudication.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing context for J7611, the typical sites of service where this medication is used, and the types of performance or administrative benchmarks and policy considerations commonly associated with HCPCS drug coding. The publication outlines how this HCPCS Level II drug code is positioned within billing workflows, common payer coverage considerations, and the operational elements stakeholders should expect when handling claims for concentrated albuterol solution supplied for use with DME.
Data not available in the input includes specific payer rates, related codes, ICD-10 mappings, and taxonomies; those items are noted as unavailable where relevant.
Billing Code Overview
HCPCS Level II code J7611 describes albuterol inhalation solution, an FDA-approved final product in a non-compounded, concentrated formulation, provided in a 1 mg strength. The code denotes the drug product itself when supplied for administration through durable medical equipment (DME) for inhalation therapy.
Service Type: Medication administration via inhalation solution supplied for use with DME
Typical Site of Service: Home or outpatient settings where DME nebulizers or inhalation devices are used
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric patient with reactive airway disease or acute bronchospasm who requires nebulized short-acting beta-agonist therapy delivered via durable medical equipment (DME) in a clinic, hospital outpatient department, or home health setting. The medication is J7611 — albuterol inhalation solution, FDA-approved final product, non‑compounded, concentrated form, 1 mg — supplied to be administered through a nebulizer connected to DME.
A realistic workflow: the patient presents with wheeze, dyspnea, or an exacerbation of asthma or chronic obstructive pulmonary disease (COPD). The clinician documents indication, orders nebulized albuterol solution and identifies the delivery method (DME nebulizer). Nursing or respiratory therapy prepares the concentrated solution, dilutes per manufacturer instructions if required, loads the nebulizer cup, and administers via the DME device while monitoring respiratory status, oxygen saturation, heart rate, and response. Post‑treatment documentation includes medication name and dose (J7611), route (inhalation via DME), time administered, patient tolerance, and any adverse effects. In home settings, DME suppliers dispense J7611 with instructions and documentation of training for caregiver administration and may bill based on delivery and medical necessity documentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|